Get the Stockscreener App
182.47
0.44%
0.9992
Krystal Biotech Inc stock is traded at $182.47, with a volume of 25,270.
It is up +0.44% in the last 24 hours and up +26.85% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$181.47
Open:
$182.44
24h Volume:
25,270
Relative Volume:
0.07
Market Cap:
$5.28B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
61.03
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
+0.94%
1M Performance:
+26.85%
6M Performance:
+10.46%
1Y Performance:
+1.99%
1-Day Range:
$179.19
$182.60
1-Week Range:
$179.19
$190.01
52-Week Range:
$122.80
$207.84
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
182.26 | 5.25B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.52 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.57 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.93 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech Inc. stock trend forecastJuly 2025 Outlook & Technical Pattern Based Buy Signals - newser.com
Is Krystal Biotech Inc. meeting your algorithmic filter criteriaIndex Update & Weekly Stock Performance Updates - newser.com
Krystal Biotech Inc. stock outlook for YEARJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Will Krystal Biotech Inc. (4KB) stock outperform Dow Jones2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com
What machine learning models say about Krystal Biotech Inc.2025 Support & Resistance & Short-Term High Return Ideas - newser.com
Is Krystal Biotech Inc 4KB a good long term investmentCandlestick Trading Patterns & Budget Investment Success - earlytimes.in
I See Some Speculative Wins Starting to Krystal-ize - TheStreet Pro
What high frequency data says about Krystal Biotech Inc.2025 Momentum Check & Fast Gain Stock Tips - newser.com
Published on: 2025-10-10 04:55:37 - newser.com
Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher - simplywall.st
Sentiment analysis tools applied to Krystal Biotech Inc.Trade Exit Report & Technical Entry and Exit Alerts - newser.com
How Krystal Biotech Inc. stock reacts to Fed rate cutsCEO Change & AI Forecasted Entry/Exit Points - newser.com
Is Krystal Biotech Inc. (4KB) stock a buy for dividend portfoliosTrade Performance Summary & Growth Focused Stock Pick Reports - newser.com
How Krystal Biotech Inc. (4KB) stock reacts to monetary easingTrade Analysis Summary & Comprehensive Market Scan Insights - newser.com
Will Krystal Biotech Inc. (4KB) stock see valuation expansionTrend Reversal & Safe Capital Growth Trade Ideas - newser.com
What’s the recovery path for long term holders of Krystal Biotech Inc.Weekly Trading Summary & Community Verified Trade Signals - newser.com
Is Krystal Biotech Inc. (4KB) stock worth buying before Fed action2025 Dividend Review & Risk Managed Investment Strategies - newser.com
Krystal Biotech Hits Day High with 9.54% Surge in Strong Performance - Markets Mojo
Signal strength of Krystal Biotech Inc. stock in tech scannersJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com
Applying Elliott Wave Theory to Krystal Biotech Inc.Trade Risk Summary & Real-Time Chart Pattern Alerts - newser.com
Analyzing drawdowns of Krystal Biotech Inc. with statistical toolsSell Signal & Weekly Return Optimization Alerts - newser.com
Exploring 3 High Growth Tech Stocks in the US Market - Yahoo Finance
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? - MSN
Krystal Biotech Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner - Sahm
Tealwood Asset Management Inc. Invests $1.13 Million in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech, Inc. (KRYS) Stock Analysis: Uncovering a 22% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Potential 22% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Tempus Wealth Planning LLC Takes Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Krystal Biotech Inc Stock (KRYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Krishnan Suma | President, R&D |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,389 |
208,350 |
1,508,056 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,435 |
2,019,225 |
1,443,276 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Krish S | President and CEO |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
0.11%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):